Greenwich LifeSciences Inc. (GLSI)
NASDAQ (CM) NASDAQ (CM) Primary Summary
GLSI Chart
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data.
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors. After March 31, 2026, the quantity of these locked-up shares that can be sold daily and over various periods of time will be restricted unless otherwise modified by the Board of Directors.
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label safety data.
Greenwich LifeSciences Inc. Dividends
Greenwich LifeSciences Inc. Earnings
| 19 May 2025 Date | | - Cons. EPS | - EPS |
| 8 Nov 2024 Date | | - Cons. EPS | - EPS |
| 1 Nov 2024 Date | | - Cons. EPS | - EPS |
| 25 Oct 2024 Date | | - Cons. EPS | - EPS |
| 17 Oct 2024 Date | | - Cons. EPS | - EPS |
| 19 May 2025 Date | | - Cons. EPS | - EPS |
| 8 Nov 2024 Date | | - Cons. EPS | - EPS |
| 1 Nov 2024 Date | | - Cons. EPS | - EPS |
| 25 Oct 2024 Date | | - Cons. EPS | - EPS |
| 17 Oct 2024 Date | | - Cons. EPS | - EPS |
Greenwich LifeSciences Inc. (GLSI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Greenwich LifeSciences Inc. ever had a stock split?
Greenwich LifeSciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Snehal S. Patel CEO | NASDAQ (CM) Exchange | 396879108 Cusip |
| US Country | 4 Employees | - Last Dividend | - Last Split | 25 Sep 2020 IPO Date |
Overview
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of novel cancer immunotherapies targeting breast cancer and other cancers expressing the HER2/neu protein. The company embarked on its journey in the healthcare sector in 2006, initially operating under the name Norwell, Inc. before rebranding to Greenwich LifeSciences, Inc. in March 2018. With its headquarters situated in Stafford, Texas, Greenwich LifeSciences has dedicated itself to the advancement of cancer treatment options through immunotherapeutic approaches, aiming to significantly improve patient outcomes in the fight against cancer.
Products and Services
- GP2 Immunotherapy
At the core of Greenwich LifeSciences’ product pipeline is GP2, an innovative immunotherapy treatment designed to prevent the recurrence of breast cancer in patients who have previously undergone surgery. Currently in Phase III clinical trials, GP2 represents a breakthrough in cancer care, offering hope for durable remission by harnessing the body's immune system to fight off cancer cells. The focus on HER2/neu-expressing cancers positions GP2 as a crucial development in the realm of oncology, potentially setting new standards for cancer immunotherapy treatments.
Contact Information
